Alaunos Prices $1.1M Registered Direct Offering at $1.46/Share
TCRT sits 24% above its 52-week low of $1.02.
Summary
Alaunos Therapeutics priced a $1.1 million registered direct offering at $1.46 per share, with pre-funded warrants at $1.459 each, to fund working capital amid a critical cash shortage and Nasdaq listing deficiency.
Key Events · Financing and Capital Events · TCRT
-
Registered Direct Offering Priced
Offering of 380,469 common shares at $1.46 per share and pre-funded warrants for 386,654 shares at $1.459 each, for aggregate gross proceeds of approximately $1.1 million.
-
Best-Efforts Structure
No minimum offering amount; Dawson James Securities is acting as sole placement agent on a reasonable best-efforts basis, so actual proceeds may be substantially less than the maximum.
-
Dilution Impact
Net tangible book value per share increases from $0.26 to $0.47, resulting in immediate dilution of $0.99 per share to purchasers.
-
Placement Agent Fees
Cash fee of 8.0% of gross proceeds plus expense reimbursement up to $40,000 and $10,000 for blue sky counsel; net proceeds estimated at $915.4 thousand.
Analysis · TCRT · Life Sciences
Alaunos Therapeutics is raising approximately $1.1 million in gross proceeds through a registered direct offering of 380,469 common shares at $1.46 per share plus pre-funded warrants for 386,654 shares at $1.459 each. The company is in a critical cash position — its last 10-Q reported only $0.35 million in cash, sufficient only into Q2 2026 — so this capital raise is essential to extend its runway. However, the offering is being made on a best-efforts basis with no minimum amount, meaning actual proceeds could be substantially less than the maximum. The deal also carries an 8% placement agent fee and will dilute existing shareholders by approximately $0.99 per share in net tangible book value. Against the backdrop of a Nasdaq delisting notice for stockholders' equity deficiency and a going-concern warning from its auditor, this financing is a survival move that buys time but does not resolve the company's fundamental cash constraints.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCRT was trading at $1.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $1.02 to $4.59. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.